MeMed is a healthcare technology startup that operates in the medical diagnostics market. The company has developed a unique technology that can accurately distinguish between bacterial and viral infections in just 15 minutes. This is a significant advancement in the field, as these types of infections are often clinically indistinguishable, leading to incorrect treatment and misuse of antibiotics. MeMed's technology is based on two key products: MeMed BV®, the first FDA-cleared host-immune response assay, and MeMed Key®, a compact immunoassay platform that enables quick, sensitive protein measurements.

The company's primary clients are physicians and healthcare providers who manage patients with acute infections. By using MeMed's technology, these professionals can make more informed decisions about patient treatment, potentially improving patient outcomes and reducing unnecessary antibiotic use.

MeMed's business model is likely based on selling its diagnostic products to healthcare providers and potentially charging for ongoing usage or services. The company's technology has been validated in multinational, double-blind clinical studies involving over 20,000 subjects in Europe, Israel, and the United States, demonstrating its effectiveness across different clinical settings and patient groups.

Keywords: Healthcare Technology, Medical Diagnostics, Bacterial Infections, Viral Infections, FDA-Cleared, Immunoassay Platform, Protein Measurements, Antibiotic Misuse, Clinical Studies, Patient Management.